Logo image of SCPH

SCPHARMACEUTICALS INC (SCPH) Stock Fundamental Analysis

NASDAQ:SCPH - Nasdaq - US8106481059 - Common Stock - Currency: USD

4.48  +0.1 (+2.28%)

After market: 4.48 0 (0%)

Fundamental Rating

2

Overall SCPH gets a fundamental rating of 2 out of 10. We evaluated SCPH against 193 industry peers in the Pharmaceuticals industry. SCPH has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, SCPH is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SCPH had negative earnings in the past year.
In the past year SCPH has reported a negative cash flow from operations.
SCPH had negative earnings in each of the past 5 years.
In the past 5 years SCPH always reported negative operating cash flow.
SCPH Yearly Net Income VS EBIT VS OCF VS FCFSCPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

SCPH has a Return On Assets of -99.80%. This is in the lower half of the industry: SCPH underperforms 75.65% of its industry peers.
Industry RankSector Rank
ROA -99.8%
ROE N/A
ROIC N/A
ROA(3y)-55.62%
ROA(5y)-46.38%
ROE(3y)-279.13%
ROE(5y)-185.24%
ROIC(3y)N/A
ROIC(5y)N/A
SCPH Yearly ROA, ROE, ROICSCPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K 5K

1.3 Margins

Looking at the Gross Margin, with a value of 68.92%, SCPH is in the better half of the industry, outperforming 76.68% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for SCPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SCPH Yearly Profit, Operating, Gross MarginsSCPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

3

2. Health

2.1 Basic Checks

SCPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SCPH has more shares outstanding
Compared to 5 years ago, SCPH has more shares outstanding
SCPH has a worse debt/assets ratio than last year.
SCPH Yearly Shares OutstandingSCPH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
SCPH Yearly Total Debt VS Total AssetsSCPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -5.49, we must say that SCPH is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of SCPH (-5.49) is worse than 63.21% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.49
ROIC/WACCN/A
WACC10.7%
SCPH Yearly LT Debt VS Equity VS FCFSCPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

SCPH has a Current Ratio of 5.48. This indicates that SCPH is financially healthy and has no problem in meeting its short term obligations.
SCPH has a better Current ratio (5.48) than 73.58% of its industry peers.
SCPH has a Quick Ratio of 4.61. This indicates that SCPH is financially healthy and has no problem in meeting its short term obligations.
SCPH's Quick ratio of 4.61 is fine compared to the rest of the industry. SCPH outperforms 69.43% of its industry peers.
Industry RankSector Rank
Current Ratio 5.48
Quick Ratio 4.61
SCPH Yearly Current Assets VS Current LiabilitesSCPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

SCPH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -29.05%.
The Revenue has grown by 138.02% in the past year. This is a very strong growth!
EPS 1Y (TTM)-29.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.78%
Revenue 1Y (TTM)138.02%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%92.59%

3.2 Future

The Earnings Per Share is expected to grow by 24.25% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 54.53% on average over the next years. This is a very strong growth
EPS Next Y43.9%
EPS Next 2Y35.85%
EPS Next 3Y32.42%
EPS Next 5Y24.25%
Revenue Next Year105.36%
Revenue Next 2Y88.94%
Revenue Next 3Y76.78%
Revenue Next 5Y54.53%

3.3 Evolution

SCPH Yearly Revenue VS EstimatesSCPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
SCPH Yearly EPS VS EstimatesSCPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SCPH. In the last year negative earnings were reported.
Also next year SCPH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SCPH Price Earnings VS Forward Price EarningsSCPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SCPH Per share dataSCPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

SCPH's earnings are expected to grow with 32.42% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.85%
EPS Next 3Y32.42%

More info and screens

0

5. Dividend

5.1 Amount

SCPH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SCPHARMACEUTICALS INC

NASDAQ:SCPH (7/14/2025, 8:03:51 PM)

After market: 4.48 0 (0%)

4.48

+0.1 (+2.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners58.37%
Inst Owner Change0%
Ins Owners6.08%
Ins Owner Change-2.89%
Market Cap236.50M
Analysts83.64
Price Target15.47 (245.31%)
Short Float %4.57%
Short Ratio5.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.21%
Min EPS beat(2)-21.73%
Max EPS beat(2)9.3%
EPS beat(4)1
Avg EPS beat(4)-41.15%
Min EPS beat(4)-147.99%
Max EPS beat(4)9.3%
EPS beat(8)4
Avg EPS beat(8)-16.53%
EPS beat(12)7
Avg EPS beat(12)-8.07%
EPS beat(16)11
Avg EPS beat(16)-1.41%
Revenue beat(2)0
Avg Revenue beat(2)-1.17%
Min Revenue beat(2)-1.43%
Max Revenue beat(2)-0.92%
Revenue beat(4)0
Avg Revenue beat(4)-3.07%
Min Revenue beat(4)-9%
Max Revenue beat(4)-0.92%
Revenue beat(8)3
Avg Revenue beat(8)0.62%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-2.05%
EPS NQ rev (3m)-13.74%
EPS NY rev (1m)-2.77%
EPS NY rev (3m)-12.35%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.2%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.36%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.63
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.91
EYN/A
EPS(NY)-0.29
Fwd EYN/A
FCF(TTM)-1.33
FCFYN/A
OCF(TTM)-1.33
OCFYN/A
SpS0.8
BVpS-0.1
TBVpS-0.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -99.8%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.92%
FCFM N/A
ROA(3y)-55.62%
ROA(5y)-46.38%
ROE(3y)-279.13%
ROE(5y)-185.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.48
Quick Ratio 4.61
Altman-Z -5.49
F-Score2
WACC10.7%
ROIC/WACCN/A
Cap/Depr(3y)23.53%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-29.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.78%
EPS Next Y43.9%
EPS Next 2Y35.85%
EPS Next 3Y32.42%
EPS Next 5Y24.25%
Revenue 1Y (TTM)138.02%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%92.59%
Revenue Next Year105.36%
Revenue Next 2Y88.94%
Revenue Next 3Y76.78%
Revenue Next 5Y54.53%
EBIT growth 1Y-11.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year26.6%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-60.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-60.13%
OCF growth 3YN/A
OCF growth 5YN/A